ClinicalTrials.gg
CompletedNCT05147051Updated Oct 5, 2022

Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

A Phase 2 interventional study of Meglumine Sodium Succinate and Placebo in Metabolic Acidosis, sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Completed at 6 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-05.

Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2021, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

An acid-base imbalance, called metabolic acidosis (acid-base disorder lasting from several minutes to several days, caused by a decrease in serum bicarbonate ion (HCO3) concentration), is often observed in critically ill patients with various underlying diseases. Metabolic acidosis has a negative impact on the cardiovascular, respiratory, digestive, nervous, excretory, hematological, endocrine, musculoskeletal and immune systems and is associated with unfavourable outcomes. Reamberin® is a solution of disubstituted sodium salt of succinic acid, which has an alkaline reaction and succinate is capable to integrate into the Krebs cycle and restore energy metabolism in the cell. The aim of the present study is to evaluate the efficacy and safety of meglumine sodium succinate at a dose of 500 to 3000 ml in critically ill patients with metabolic acidosis and choose the optimal volume of its solution for the correction of metabolic acidosis in critically ill patients.

02

Conditions studied

  • Metabolic Acidosis

Keywords

  • metabolic acidosis
  • critical illness
  • acid-base disorder
03

In context

Acidosis

111 studies on the registry are indexed under Acidosis; 19 are open to participants now.

This study's enrollment of 140 is above the median of 52 across 79 interventional studies indexed under Acidosis.

Browse Acidosis studies →

Lead sponsor

POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated written (if unconscious due to a critical condition, the decision is made by a Council consisting of 3 physicians)
  2. Male and female patients aged 18-70
  3. Critical illness ((shock (including traumatic, hypovolemic), major trauma, acute massive blood loss, acute complicated surgical diseases of the abdominal organs) accompanied by metabolic acidosis, defined as serum bicarbonate \<22mmol/L
  4. pH of arterial blood 7.20-7.35, inclusive
  5. Planned volume of infusion >= 1500 ml per day
  6. Interval between admission to the ICU and randomization \<24 hours

Exclusion criteria

Exclusion Criteria:

  1. Pregnant and lactating women
  2. Known to any component of the study drug / placebo
  3. Chronic kidney disease stage C5 (end-stage renal failure)
  4. Acute hepatic failure ( > 15 upper normal limits) or liver cirrhosis
  5. Traumatic brain injury accompanied by cerebral edema
  6. Previously diagnosed mental illness
  7. Any chronic disease in the terminal stage with a of \< 3 months
  8. infection
  9. cardiovascular disease (unstable angina pectoris or angina pectoris of functional class III or higher; chronic heart failure III - IV class according to ; acute myocardial infarction within 6 months before screening)
  10. Extremely low or extremely high body fat
  11. Infusion sodium bicarbonate, sodium bicarbonate, trometamol, Sterofundin, Quintasol, Ringer's lactate (Hartmann's solution) within 6 hours before screening
  12. Acute respiratory acidosis
  13. Poisoning with chemical compounds causing metabolic acidosis
  14. Alcohol in saliva at screening >= 0.5 pro mille
  15. Previously diagnosed
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Reamberin group

    Patients receive the investigational treatment (meglumine sodium succinate), 500 ml intravenously every 8 hours (up to 6 infusions).

    Drug: Meglumine Sodium Succinate

  • Placebo comparator
    Placebo

    Patients receive a Placebo (Ringer's solution), 500 ml intravenously every 8 hours (up to 6 infusions).

    Drug: Placebo

Interventions

  • DrugMeglumine Sodium Succinate

    500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute

  • DrugPlacebo

    Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute

06

What researchers measure

Primary outcomes

  1. Elimination of acidosis at 24 hours after the start of treatment

    The proportion of patients who have achieved normalization of the serum bicarbonate level (normalization = serum hydrocarbonate ion concentration ≥22 mmol / Liter), at 24 hours after the start of therapy.

    Time frame: 24 hours

07

Study locations

6 sites
  • GBUZ Arkhangelsk region "First GKB named after E.E. Volosevich"
    Arkhangel'sk, 163001, Russian Federation
  • Ivanovo Regional Clinical Hospital
    Ivanovo, 152040, Russian Federation
  • Central Clinical Hospital with a polyclinic of the Office of the President of the Russian Federation
    Moscow, Russian Federation
  • Privolzhsky District Medical Center
    Nizhny Novgorod, 603001, Russian Federation
  • Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine
    Saint Petersburg, Russian Federation
  • National Research Mordovian State University n.a. N.P. Ogarev
    Saransk, 430005, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in May 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Dec 7, 2021
StartActual
Jun 16, 2021
Primary completionActual
May 23, 2022
CompletionActual
Jun 22, 2022
Last update
Oct 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05147051
Collaborators
Atlant Clinical Ltd.
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Jun 16, 2021
Primary completion
May 23, 2022
Completion
Jun 22, 2022
Last update
Oct 5, 2022

Study contacts

Mikhail Yu Kirov
principal investigator · GBUZ Arkhangelsk region "First GKB named after E.E. Volosevich"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion